Are heated tobacco products a healthy alternative to cigarettes? Review article

Main Article Content

Anna Romaszko-Wojtowicz
Anna Doboszyńska


As well as being an extremely widespread addiction, tobacco smoking is a well-known cause of numerous deaths around the world. Most (80–90%) of lung cancer cases occur among smokers. The awareness of harmful effects of smoking is growing constantly. Manufacturers of tobacco products have recently opted to face this challenge by marketing heated tobacco products. Based on the performed research, tobacco companies maintain that these products are less harmful. They advertise their products as a smokeless, unconventional, less harmful cigarette. Due to the short follow-up period, the studies on consequences of using heated tobacco products are still scarce. This article presents a review of the literature focused on the use of heated tobacco products as an alternative to traditional cigarettes.


Metrics Loading ...

Article Details

How to Cite
Romaszko-Wojtowicz A, Doboszyńska A. Are heated tobacco products a healthy alternative to cigarettes?. OncoReview [Internet]. 2021Mar.31 [cited 2021Jun.22];11(1(41):5-11. Available from:


1. Chapman S, Wakefield MA. Large-scale unassisted smoking cessation over 50 years: lessons from history for endgame planning in tobacco control. Tob Control. 2013; 22(suppl 1): i33-5.
2. Ludicke F, Picavet P, Baker G et al. Effects of Switching to the Tobacco Heating System 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1). Nicotine Tob Res. 2018; 20(2): 161-72.
3. Ludicke F, Picavet P, Baker G et al. Effects of Switching to the Menthol Tobacco Heating System 2.2, Smoking Abstinence, or Continued Cigarette Smoking on Clinically Relevant Risk Markers: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 2). Nicotine Tob Res. 2018; 20(2): 173-82.
4. Philips Morrison International. (access: 5.02.2021).
5. Jaccard G, Tafin Djoko D, Moennikes O et al. Comparative assessment of HPHC yields in the Tobacco Heating System THS2.2 and commercial cigarettes. Regul Toxicol Pharmacol. 2017; 90: 1-8.
6. Pratte P, Cosandey S, Goujon Ginglinger C. Investigation of solid particles in the mainstream aerosol of the Tobacco Heating System THS2.2 and mainstream smoke of a 3R4F reference cigarette. Hum Exp Toxicol. 2017; 36(11): 1115-20.
7. Wong ET, Kogel U, Veljkovic E et al. Evaluation of the Tobacco Heating System 2.2. Part 4: 90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects compared with cigarette smoke. Regul Toxicol Pharmacol. 2016; 81(suppl 2): S59-S81.
8. Schaller JP, Keller D, Poget L et al. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul Toxicol Pharmacol. 2016; 81(suppl 2): S27-S47.
9. Hagemejer J, Malinowska A, Poniatowski G et al. Wpływ produkcji wyrobów tytoniowych na Polską gospodarkę. Centrum Analiz Społeczno-Rynkowych, Warszawa 2020.
10. Drope J, Schluger NW. The tobacco atlas. American cancer society; 2018.
11. Borland R, Partos TR, Yong HH et al. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control Four Country cohort survey. Addiction. 2012; 107(3): 673-82.
12. Kaidar-Person O, Bar-Sela G, Person B. The two major epidemics of the twenty-first century: obesity and cancer. Obes Surg. 2011; 21(11): 1792-7.
13. U.S. Department of Health and Human Services . The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Atlanta, GA, USA: 2014: 1-36.
14. Secretan B, Straif K, Baan R et al. A review of human carcinogens – Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009; 10(11): 1033-4.
15. Agudo A, Bonet C, Travier N et al. Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. J Clin Oncol. 2012; 30(36): 4550-7.
16. Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004; 328(7455): 1519. .
17. Kiiskinen U, Vartiainen E, Puska P et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens. 1998; 16(8): 1103-12.
18. Hay SI, Abajobir AA, Abate KH et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1260-344.
19. Cheng TY, Cramb SM, Baade PD et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016; 11(10): 1653-71.
20. Young People Oncology Foundation Alivia and prepared by EY Poland. Access to innovative cancer drugs in Poland in comparison with selected European Union countries and Switzerland. 2015.
21. Potrykowska A, Strzelecki Z, Szymborski J et al. Zachorowalność i umieralność na nowotwory a sytuacja demograficzna Polski. Rządowa Rada Ludnościowa; 2014.
22. Didkowska J, Wojciechowska U. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. (access: 6.02.2021).
23. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-86.
24. Malik K. Human development report 2013. The rise of the South: Human progress in a diverse world. The Rise of the South: Human Progress in a Diverse World (March 15, 2013) UNDP-HDRO Human Development Reports. 2013.
25. Calm J. The cancer problem. Sci Am. 1975; 233: 64-78.
26. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Translational lung cancer research. 2015; 4(4): 327.
27. Tindle HA, Stevenson Duncan M, Greevy RA et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. J Natl Cancer Inst. 2018; 110(11): 1201-7.
28. Mallock N, Pieper E, Hutzler C et al. Heated Tobacco Products: A Review of Current Knowledge and Initial Assessments. Front Public Health. 2019; 7: 287.
29. Lee A, Lee SY, Lee KS. The use of heated tobacco products is associated with asthma, allergic rhinitis, and atopic dermatitis in Korean adolescents. Scientific Reports. 2019; 9(1): 1-8.
30. Chun L, Moazed F, Matthay M et al. Possible hepatotoxicity of IQOS. Tob Control. 2018; 27(suppl 1): s39-s40. 2018-054320.
31. Glantz S, Slade J, Bero L. Chaper 4: The search for a “safe” cigarette. University of California Press Berkeley; 1996.
32. General USPHSOotS, Prevention NCfCD, Smoking HPOo. Preventing tobacco use among youth and young adults: a report of the surgeon general. US Government Printing Office; 2012.
33. Elias J, Dutra LM, Helen GS et al. Revolution or redux? Assessing IQOS through a precursor product. Tobacco Control. 2018; 27(suppl 1): s102-s10.
34. Tobacco Tactics. Next Generation Products: British American Tobacco. (access: 5.02.2021)
35. Glantz SA. Heated tobacco products: the example of IQOS. Tob Control. 2018; 27(suppl 1): s1-s6.
36. Caputi TL. Industry watch: heat-not-burn tobacco products are about to reach their boiling point. Tob Control. 2016; 26(5): 609-10.
37. Eaton D, Jakaj B, Forster M et al. Assessment of tobacco heating product THP1.0. Part 2: Product design, operation and thermophysical characterisation. Regul Toxicol Pharmacol. 2018; 93: 4-13.
38. Smith MR, Clark B, Ludicke F et al. Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regul Toxicol Pharmacol. 2016; 81(suppl 2): S17-S26.
39. Ludicke F, Haziza C, Weitkunat R et al. Evaluation of Biomarkers of Exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study. Nicotine Tob Res. 2016; 18(7): 1606-13.
40. Simonavicius E, McNeill A, Shahab L et al. Heat-not-burn tobacco products: a systematic literature review. Tob Control. 2019; 28(5): 582-94.
41. Leigh NJ, Tran PL, O’Connor RJ et al. Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells. Tob Control. 2018; 27(suppl 1): s26-s9.
42. Neilsen K, Glantz SA. A tobacco industry study of airline cabin air quality: dropping inconvenient findings. Tob Control. 2004; 13(suppl 1): i20-9.
43. Wertz MS, Kyriss T, Paranjape S et al. The toxic effects of cigarette additives. Philip Morris’ project mix reconsidered: an analysis of documents released through litigation. PLoS Med. 2011; 8(12): e1001145.
44. El-Toukhy S, Baig SA, Jeong M et al. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents. Tob Control. 2018; 27(suppl 1): s62-s9.
45. Gentzke AS, Wang TW, Jamal A et al. Tobacco Product Use Among Middle and High School Students – United States, 2020. Morbidity and Mortality Weekly Report. 2020; 69(50): 1881.
46. Osibogun O, Taleb ZB, Bahelah R et al. Correlates of poly-tobacco use among youth and young adults: Findings from the Population Assessment of Tobacco and Health study, 2013-2014. Drug Alcohol Depend. 2018; 187: 160-4.
47. Leas EC, Cohen JE, Ayers JW. A Philip Morris advertisement for its heated tobacco product IQOS sets a troubling precedent. Tobacco Control 2020; 29(e1): e168-e70.
48. U.S. Federal Trade Commission (FTC). Cigarette Report 2018. 2018.
49. Kim M, Watkins SL, Koester KA et al. Unboxed: US Young Adult Tobacco Users’ Responses to a New Heated Tobacco Product. Int J Environ Res Public Health. 2020; 17(21).
50. Churchill V, Weaver SR, Spears CA et al. IQOS debut in the USA: Philip Morris International’s heated tobacco device introduced in Atlanta, Georgia. Tob Control. 2020; 29(e1): e152-e4.
51. Lee CM. The Impact of Heated Tobacco Products on Smoking Cessation, Tobacco Use, and Tobacco Sales in South Korea. Korean J Fam Med. 2020; 41(5): 273-81.
52. Tabuchi T, Gallus S, Shinozaki T et al. Heat-not-burn tobacco product use in Japan: its prevalence, predictors and perceived symptoms from exposure to secondhand heat-not-burn tobacco aerosol. Tob Control. 2018; 27(e1): e25-e33.
53. Hair EC, Bennett M, Sheen E et al. Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland. Tobacco Control. 2018; 27(suppl 1): s70-s3.
54. Dyrektywa Parlamentu Europejskiego i Rady 2014/40/UE z dnia 3 kwietnia 2014 r. w sprawie zbliżenia przepisów ustawowych, wykonawczych i administracyjnych państw członkowskich w sprawie produkcji, prezentowania i sprzedaży wyrobów tytoniowych i powiązanych wyrobów oraz uchylająca dyrektywę 2001/37/WE.
55. Morean ME, Butler ER, Bold KW et al. Preferring more e-cigarette flavors is associated with e-cigarette use frequency among adolescents but not adults. PloS ONE. 2018; 13(1): e0189015.
56. Du P, Bascom R, Fan T et al. Changes in Flavor Preference in a Cohort of Long-Term Electronic Cigarette Users. Ann Am Thorac Soc. 2020; 17(5): 573-81. .
57. Berg CJ. Preferred flavors and reasons for e-cigarette use and discontinued use among never, current, and former smokers. Int J Public Health. 2016; 61(2): 225-36.
58. Forster M, Fiebelkorn S, Yurteri C et al. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol. 2018; 93: 14-33.
59. Caponnetto P, Maglia M, Prosperini G et al. Carbon monoxide levels after inhalation from new generation heated tobacco products. Respir Res. 2018; 19(1): 164. .
60. Adriaens K, Gucht DV, Baeyens F. IQOS(TM) vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence. Int J Environ Res Public Health. 2018; 15(12).
61. Baker R. The formation of the oxides of carbon by the pyrolysis of tobacco. Beiträge zur Tabakforschung International/Contributions to Tobacco Research. 1975; 8(1): 16-27.
62. Herod AA, Kandiyoti R. Pyrolysis. (access: 7.02.2021).
63. Food and Drug Administration FDA Briefing Document: January 24-25, 2018 TPSAC Meeting. 2018. Committees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/UCM593109.pdf (access: 5.02.2021).
64. Food and Drug Administration (FDA). 2019 premarket tobacco product marketing orders. 2019. tobacco-product-applications/premarket-tobacco-product-marketing-orders (access: 7.02.2021).
65. Gale N, McEwan M, Camacho OM et al. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to the glo Tobacco Heating Product: A Randomized, Controlled Ambulatory Study. Nicotine Tob Res. 2020.
66. Miura N, Yuki D, Minami N et al. A study to investigate changes in the levels of biomarkers of exposure to selected cigarette smoke constituents in Japanese adult male smokers who switched to a non-combustion inhaler type of tobacco product. Regul Toxicol Pharmacol. 2015; 71(3): 498-506.
67. Cho H, Kim H, Lee C et al. Analysis on use pattern of heated tobacco products and their impact on quit smoking intention. Sejong: Ministry of Health and Welfare. 2018.
68. St Helen G, Jacob Iii P, Nardone N et al. IQOS: examination of Philip Morris International’s claim of reduced exposure. Tob Control. 2018; 27\ (suppl 1): s30-s6.